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Summary
Background Despite international recommendations, coverage of syphilis testing in pregnant women and treatment 
of those found seropositive remains limited in sub-Saharan Africa. We assessed whether combining the provision 
of supplies with a behavioural intervention was more effective than providing supplies only, to improve syphilis 
screening and treatment during antenatal care.
Methods In this 18-month, cluster randomised controlled trial, we randomly assigned (1:1) 26 urban antenatal care 
clinics in Kinshasa, Democratic Republic of the Congo, and Lusaka, Zambia, to receive a behavioural intervention 
(opinion leader selection, academic detailing visits, reminders, audits and feedback, and supportive supervision) plus 
supplies for syphilis testing and treatment (intervention group) or to receive supplies only (control group). The 
primary outcomes were proportion of pregnant women who had syphilis screening out of the total who attended the 
clinic; and the proportion of women who had treatment with benzathine benzylpenicillin out of those who tested 
positive for syphilis at their first antenatal care visit. This trial is registered at ClinicalTrials.gov, number NCT02353117.
Findings The 18-month study period was Feb 1, 2016, to July 14, 2017. 18 357 women were enrolled at the 13 intervention 
clinics and 17 679 women were enrolled at the 13 control clinics at their first antenatal care visit. Syphilis screening 
was done in a median of 99·9% (IQR 99·0–100·0) of women in the intervention clinics and 93·8% (85·0–98·9) in 
the control clinics (absolute difference 6·1% [95% CI 1·1–14·1]; p=0·00092). Syphilis treatment at the first visit was 
done in a median of 100% (IQR 99·7–100·0) of seropositive women in intervention clinics and 43·2% (2·6–83·2) of 
seropositive women in control clinics (absolute difference 56·8% [12·8–99·0]; p=0·0028).
Interpretation A behavioural intervention, together with the provision of supplies, can lead to more than 95% of 
women being screened and treated for syphilis. The sole provision of supplies is sufficient to reach such levels of 
screening coverage but is not sufficient to ensure high levels of treatment.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Mother-to-child transmission of syphilis is a preventable 
major public health concern, particularly in low-income 
and middle-income countries; untreated maternal syphilis 
is associated with stillbirths, perinatal deaths, prematur-
ity, and congenital infections.1,2 Despite global incre-
mental improvements in screening and treatment, nearly 
one million pregnant women are infected with syphi lis each 
year, and without treatment, an estimated 350 000 women 
will have adverse birth outcomes.3
To eliminate mother-to-child transmission of syphilis, 
WHO recommends that coverage of syphilis testing in 
pregnant women and treatment coverage of women posi-
tive for syphilis should each be at least 95%.4,5 Despite 
these recommendations, progress in reducing maternal 
syphilis has been poor, especially in Africa, the region 
with the greatest incidence of mother-to-child syphilis 
transmission. In 2012, among women who were estim-
ated to be likely to have active syphilis, only 3% in the 
Democratic Republic of the Congo and 24% in Zambia 
were treated.3
The primary challenge to improving screening and 
treatment of syphilis during pregnancy in low-resource 
settings is often assumed to be insufficient access to 
supplies. Although there is evidence supporting this 
assumption,6,7 other implementation research suggests 
that additional interventions might be needed to overcome 
barriers related to health providers’ behaviours regarding 
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treatment and increase the likelihood that the supplies 
are used.8 To improve syphilis screening and treatment 
during pregnancy, we designed a multifaceted behavioural 
intervention based on previous research experience.8–10 We 
assessed whether combining the provision of supplies 
with a multifaceted behavioural intervention was more 
effective than providing supplies only to improve syphilis 
screening and treatment in seropositive pregnant women 
attending antenatal care clinics in Kinshasa (Democratic 
Republic of the Congo) and Lusaka (Zambia).
Methods
Study design and participants
This 18-month facility-based, two-arm, parallel cluster 
randomised implementation trial was done at 26 ante natal 
care clinics (16 in Kinshasa and ten in Lusaka). Clinics 
serving a mean of at least 300 new pregnant women per 
year, with antenatal care providers qualified to perform 
screening tests and administer injectable treatments, and 
with no active quality improvement programmes for 
syphilis detection and management were eligible. All 
women attending their first antenatal care visit at the 
participating clinics in both sites from Feb 1, 2016, to 
July 14, 2017, were eligible to partici pate. All participants 
gave written informed con sent. A detailed description of 
the antenatal care providers is included elsewhere.11 
Briefly, in both sites, ante natal care is provided by nurses, 
midwives, counsellors, and physicians.
The sites’ ethics review committees and partner insti-
tutions approved the trial (appendix). All participating 
clinics provided written agreement to participate, and 
their authorities acted as clinical ethical guardians. All 
eligible women provided written consent for data collec-
tion purposes. The protocol was in accordance with the 
Ottawa Statement.12
Randomisation and masking
After a 9-month period of baseline data collection,13 
we assigned clinics to either an intervention group or 
a control group; the data centre at the Institute for 
Clinical Effectiveness and Health Policy (Buenos Aires, 
Argentina) assigned clinics to groups using a covariate-
constrained randomisation procedure.14 This procedure 
ensured that intervention groups were balanced with 
respect to the number of women attending first antenatal 
care visits, the number of women attended per health 
provider at each clinic, the frequency of women screened 
for syphilis, the frequency of women positive for syphilis, 
the type of clinic, and the country.
The study statisticians (EBe and LG) did the ran-
domisation using the covariate infor mation from the 
baseline data collection period. Each clinic was informed 
of the randomisation allocation after baseline data 
collection and before implementation of the intervention. 
The nature of the trial precluded masking of randomisation 
allocation.
Research in context
Evidence before this study
We did searches in PubMed and the Cochrane Library for 
systematic reviews and randomised controlled trials (RCTs) 
assessing strategies to improve syphilis screening and 
treatment in pregnant women during antenatal care. 
We searched with the terms “syphilis screening”, “syphilis 
treatment”, and “pregnancy” for items published up to 
May 1, 2018, in any language. We found two systematic 
reviews that included two cluster RCTs. Both trials compared 
clusters using point-of-care screening, test results, 
and treatment on the same day against clusters using 
conventional laboratory testing. The proportion of women 
screened at first antenatal care visit were significantly higher 
with the point-of-care strategy (99·9%) than with the 
conventional laboratory strategy (79·6%; p<0·001) in the 
Munkhuu trial; the Myer trial did not report on screening as an 
outcome. Although proportions of women treated were 
marginally significantly higher with the point-of-care strategy 
(98·9%) than with the conventional strategy (89·6%; p=0·05) 
in the Munkhuu study, they were not significantly different in 
the Myer trial (64·1% with point-of-care strategy vs 68·6% 
with conventional strategy; odds ratio 0·82; 95% CI 
0·57–1·17). Another cluster trial provided kits with supplies, 
including rapid treponemal tests, to improve screening 
practices during antenatal care in clinics in Mozambique, 
using a stepped-wedge design. The study showed an increase 
in syphilis screening from 65·7% to 95·5% (p<0·0001), as well 
as an increase in same-day treatment from 60·8% to 86·2% 
(p<0·024). We identified no published RCTs assessing the 
effect of behavioural interventions to health providers on 
syphilis screening and treatment in clinics provided with rapid 
treponemal tests.
Added value of this study
To our knowledge, this is the first randomised trial to assess 
the effect of a multifaceted behavioural intervention together 
with the provision of supplies for point-of-care syphilis 
screening and treatment in antenatal care clinics in 
sub-Saharan Africa.
Implications of all the available evidence
Audit and feedback, the use of reminders, academic detailing 
visits, and opinion leaders have been shown to be effective 
strategies targeting health-care providers to implement a 
variety of evidence-based health-care interventions. Our results 
showed that it is possible to screen and treat more than 95% of 
women at the first antenatal care visit, which is the suggested 
coverage proposed by WHO towards the elimination of 
mother-to-child transmission of syphilis. The sole provision of 
point-of-care tests can also achieve high levels of screening; 
however, it might not be enough to ensure treatment.
See Online for appendix
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Procedures
The intervention lasted for 18 months. Intervention 
strate gies combined strategies shown to change 
providers’ behaviour8–10 with those based on the diffusion 
of inno vation theory,15 with the provision of supplies for 
syphilis screening and treatment. The intervention was 
tailored by formative research with clinic administrators, 
health providers, and pregnant women, which was done 
in Kinshasa and Lusaka and reported elsewhere.16 Briefly, 
the main barriers to immediate same-day treatment 
were unawareness that one dose of benzathine benzyl-
penicillin is enough to prevent mother-to-child syphilis 
transmission and concerns about potential adverse 
reactions to benzathine benzylpenicillin.14
The behavioural strategies used in the intervention 
group consisted of selection of opinion leaders, academic 
detail ing visits with antenatal care providers, reminders, 
audits and feedback, supportive supervision, and the 
prepara tion of kits with the supplies for syphilis screen-
ing and treatment. Supplies provided to both groups 
were point-of-care rapid syphilis tests (Alere Determine 
Syphilis TP test; Alere International, UK) in Kinshasa 
and rapid immuno chromatographic tests (SD Bioline 
Syphilis 3.0 test; Standard Diagnostic, Yongin, Korea) in 
Lusaka; treatment packs of benzathine benzylpenicillin 
2·4 million inter national units (IU), syringe and needle, 
instructions and information on side-effects, and eryth-
romycin 250 mg tablets; and anaphylaxis treatment for 
emergency use according to local prac tice guidelines. 
In accordance with WHO and country guidelines,5 
all antenatal care providers were trained to administer 
one intramuscular dose of benzathine benzylpenicillin 
(2·4 million IU) to every woman with a positive syphilis 
test result at the first antenatal care visit to prevent 
mother-to-child syphilis transmission. Women who 
reported being allergic to penicillin were treated orally 
with 2 g per day of erythromycin for 14 days.
One or two antenatal care providers who were know-
ledgable, humane, and willing to share knowledge were 
identified at each intervention clinic with the use of 
a previously validated sociometric questionnaire and 
trained as facilitators for the study.17 These facilitators 
were trained by local coordinators in a 2-day workshop, 
which focused on how to screen for syphilis during 
pregnancy, training on the use of point-of-care tests, and 
how to treat and counsel pregnant women who were 
seropositive for syphilis. Additionally, facilitators were 
trained in monitoring the stock of supplies.
At the clinics, the facilitators, with the support of the 
intervention site coordinators, replicated the training for 
the rest of the antenatal care providers, and visited them 
individually to assess their views (academic detailing 
visits). Additionally, facilitators developed reminder 
materials for syphilis testing and treatment and manage-
ment of anaphylaxis and placed them in waiting rooms 
and antenatal care offices. They also packaged the sup-
plies in kits to ensure that they were readily available.
A local site coordinator did monthly supportive super-
vision activities with facilitators at each intervention clinic, 
which included monitoring intervention activities, imple-
mentation problem solving, and sharing and dis cussing 
a monthly report on the clinic’s syphilis screen ing and 
treatment activities (audit and feedback). The facilitators 
then shared and discussed these reports with all antenatal 
care providers at the clinic. Monthly, the local site 
coordinator monitored the expiration dates and assessed 
the capacity of the antenatal care providers to correctly 
interpret the results of the point-of-care test in a random 
sample of providers during the visit by direct observation.
The intervention was implemented pragmatically in the 
context of routine antenatal care. First, the Kinshasa and 
Lusaka site coordination teams received intervention 
training at a local venue. Following each site’s in-country 
central training, each site team developed a detailed 
implementation plan, identified facilitators, and then 
conducted their training at intervention clinics. At the 
clinics, the interventions started upon completion of the 
intervention training and provision of supplies. Details 
regarding the intervention in accordance with the template 
for intervention description and replication guide18 are 
described in the appendix.
Clinics in the control group continued routine antenatal 
care practice without a behavioural intervention but were 
provided with the supplies for syphilis testing and treat-
ment and training in their use.
Outcome data were collected by trained study personnel 
at all participating clinics. Women were recruited con-
secutively. For all enrolled women, study personnel 
completed an antenatal care form with data regarding the 
practices and procedures performed during the first 
antenatal care visit, namely testing for syphilis, proteinuria, 
anaemia, and HIV and information about their obstetric 
and syphilis history. These data were obtained from 
the source documents that each clinic routinely uses to 
report antenatal care practices and procedures, including 
antenatal care log books, ante natal cards, prevention of 
mother-to-child transmission books, laboratory log books, 
and nursing log books. Data not avail able in source 
documents were collected by interviewing the women.
Data were collected on paper forms and entered in 
each country into a secure web-based, open-source 
data man agement system (OpenClinica), placed into a 
password-protected server, and securely transmitted 
using end-to-end encryption. The data entry system 
allowed range and consistency checks to be done. Cross-
form edits were done at the data co-ordinating centre in 
Buenos Aires and resolved locally. We used double data 
entry to prevent data keying errors in all data forms.
Although the outcomes of the study were only measured 
at the first antenatal care visit, all women enrolled at 
participating clinics with a positive test for syphilis who did 
not receive treatment during the first visit were followed 
up by study personnel until their estimated date of delivery 
to ensure that all infected women received treatment 
For OpenClinica see 
https://www.openclinica.com/
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before delivery. Women were contacted at the subsequent 
antenatal care visits or by phone. The list of seropositive 
women who did not receive treatment at the first visit was 
communicated monthly to the country principal 
investigators to be shared with local health authorities.
Outcomes
The primary outcomes were the proportion of women 
screened for syphilis during their first antenatal care visit 
and the proportion of women with a positive syphilis test 
who were treated with benzathine benzylpenicillin (or 
erythromycin if applicable) during their first antenatal 
care visit. Secondary outcomes were the frequency of 
women screened for HIV, anaemia, and proteinuria at 
their first antenatal care visit, as other practices that 
could be affected by the behavioural intervention. We 
also did an analysis of the effects on primary outcomes 
by country; however, no statistical interaction was 
tested because the study was not designed to test such 
hypothesis.
Statistical analysis
The statistical power was estimated for the two prim -
ary outcomes under the assumption that a mean of 
300 women were initiating antenatal care per clinic each 
year and that three of them (1%) would be found sero-
positive at syphilis screening. A sample size of 20 clinics 
(ten per group) would provide more than 80% power to 
detect an increase in treatment of seropositive women at 
the first visit from 50% to 85%, with an α level of 0·025, 
and an intracluster correlation coefficient of 0·01. 
20 clinics would also provide more than 90% power to 
detect an increase in the number of women screened for 
syphilis from 50% to 75%. Our calculations were based 
on the conservative assumption that 50% of women 
were screened and 50% of those found sero positive were 
treated at the participating clinics. To allow for clinics to 
drop out or to be excluded before group assignment, we 
collected baseline data from 29 clinics.
Analyses were performed according to the intention-
to-treat principle, and no clinic was excluded from the 
analysis after allocation. All outcomes were analysed 
using the clinic as the unit of analysis. We calculated 
the proportion of all pregnant clinic attendees who 
were screened and the proportion of syphilis-positive 
women who were treated at each clinic for the 18-month 
follow-up period and compared the median propor-
tions between the intervention and control clinics. The 
absolute diff erence between median outcome rates was 
calculated as the intervention effect and tested with 
the use of the Wilcoxon rank sum test with continuity 
correction to establish the 95% CI.19 Because a restrict-
 ed randomisation procedure was used, a restricted ran-
domisation test was also done.20 The results were simi lar 
to those obtained with the non-parametric strategy. 
All analyses were done with the R statistical package, 
version 1.1.456.
The syphilis screening outcome was the proportion of 
pregnant women who were screened for syphilis in 
each participating clinic at the first antenatal care 
visit out of all pregnant women attending a first visit. 
The treat ment outcome was the proportion of women 
who were treated with one dose of benzathine 
benzylpenicillin during the first antenatal visit out of all 
women who tested seropositive at screening. Prevalence 
of syphilis infection was the number of women who 
were sero positive out of all those who were screened. 
An independent data safety monitoring board 
reviewed the progress of the trial as specified in the 
protocol. The trial is registered at ClinicalTrials.gov, 
number NCT02353117.
Role of the funding source
The funder of the study was involved in the study design 
and data interpretation and reviewed and approved 
the report, but had no role in data collection or data 
analysis. FA, MBer, MLC, KK, AC, EBe, and LG had 
access to all data in the study and the corresponding 
author had final responsibility for the decision to submit 
for publication.
Results
29 clinics completed baseline data collection, and three 
clinics in Zambia were excluded after the baseline data 
collection period, two of them because they had propor-
tions of women tested for syphilis of more than 60% and 
one for logistical reasons. 26 clinics were randomly 
assigned to either the intervention (n=13) or control (n=13) 
group (figure 1). All 26 clinics completed the trial. Baseline 
data were collected for 9282 women in the supplies plus 
Figure 1: Trial profile
29 clinics assessed for eligibility
 16 in Democratic Republic of the Congo
 13 in Zambia
26 clinics randomly assigned
 16 in Democratic Republic of the Congo
 10 in Zambia
13 clinics allocated to intervention group
 8 in Democratic Republic of the Congo
 5 in Zambia
13 clinics allocated to control group
 8 in Democratic Republic of the Congo
 5 in Zambia
13 clinics followed up at 18 months 13 clinics followed up at 18 months
13 clinics analysed 13 clinics analysed
3 clinics from Zambia were excluded 
 2 because they had screening rates of more 
  than 60% 
 1 for logistical reasons 
intervention
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clinics and for 9265 women in the control group. The 
two groups were balanced with respect to baseline 
characteristics of the clinics and the women (table 1). The 
median proportions of women screened for syphilis were 
41·4% (IQR 25·1–69·7) in the intervention clinics and 
40·9% (15·5–74·2) in the control clinics. In women 
screened and found seropositive, the median proportions 
of women treated were 0% (0·0–0·0) in the intervention 
group and 0·0% (0·0–21·7) in the control group.
Overall, intervention compliance was high. The 
behavioural components were implemented with a 
compliance rate between 88% and 100% of what was 
planned (appendix). Neither the intervention nor 
control clinics ran out of stock of supplies for screening 
and treatment during the 18-month period.
During the follow-up period, data were collected from 
18 357 women in the intervention clinics and 17 679 in the 
control clinics. The maternal characteristics did not differ 
from the baseline period or between the two trial groups 
(appendix). No data on primary outcomes were missing 
in either group.
Syphilis screening occurred in a median of 99·9% 
(IQR 99·0–100·0) of women attending the intervention 
clinics compared with 93·8% (85·0–98·9) attending the 
control clinics (table 2). The size of the intervention effect, 
measured as the median absolute difference between 
the two groups, was 6·1% (95% CI 1·1–14·1; p=0·00092). 
More than 95% of women were screened at all the 
intervention clinics (figure 2A). Of the 13 control clinics, 
six (46%) had screening proportions greater than 95% 
and seven (54%) had 68–94%. No substantial differences 
were noted between the observed effect in Kinshasa and 
Lusaka (appendix).
In the intervention clinics, a median of 100% 
(IQR 99·7–100·0) of women who were screened for 
syphilis and tested seropositive during their first visit were 
treated (table 2). However, in control clinics the propor -
tion was 43·2% (2·6–83·2). The absolute difference was 
56·8% (95% CI 12·8–99·0; p=0·0028). 12 (92%) of the 
13 intervention clinics treated more than 95% of sero-
positive women. Of the 13 control clinics, two (15%) treated 
more than 95% of women; eight (62%) treated 0–87%, 
and three clinics had no proportion calculated because 
none of the women at that clinic were seropositive during 
the follow-up period (figure 2B). In the Lusaka clinics, 
868 (6·3%) of 13 829 women in the intervention clinics and 
988 (6·8%) of 14 504 in the control clinics were seropositive 
for syphilis; in Kinshasa, 26 (0·6%) of 4485 women in 
the intervention clinics and six (0·2%) of 2529 in the con-
trol clinics were seropositive. The intervention effect on 
the treatment outcome was different between Kinshasa 
(100·0%) and Lusaka (44·6%; appendix).
For both outcomes, increases were observed after the 
9-month baseline period, at the time when distribution of 
supplies to both trial groups was initiated (figure 3). 
Proportions of seropositive women treated in the control 
group increased slightly over time.
Regarding the secondary outcomes, no statistically or 
clinically significant differences were recorded in the 
proportions of women screened for anaemia, HIV, and 
proteinuria between the intervention and control clinics 
(table 2).
We followed up all seropositive women that were not 
treated at their first visit, irrespective of trial group. In all 
26 clinics, 462 women who tested seropositive at screen-
ing were not treated at their first visit; 383 (83%) of 
462 were followed up during pregnancy and 380 (99%) of 
these 383 women received at least one dose of benzathine 
benzylpenicillin.
Intervention group Control group
Number of clinics 13 13
Number of women 9282 9265
Number of women 
per clinic
1412 (1461) 1360 (1450)
Country
Democratic Republic of 
the Congo
8 (62%) 8 (62%)
Zambia 5 (38%) 5 (38%)
Type of clinic
Public 7 (54%) 8 (62%)
Private 2 (15%) 1 (8%)
Faith-based 4 (31%) 4 (31%)
Clinic with syphilis or HIV 
programme
12 (92%) 12 (92%)
Number of first antenatal 
care clinic visits per clinic
491 (194–894) 337 (192–1225)
Number of first antenatal 
care clinic visits 
per health provider
129 (65–192) 81 (64–153)
Screened for syphilis 41·4% (25·1–69·7) 40·9% (15·5–74·2)
Positive for syphilis 1·2% (0·2–1·6) 1·1% (0·0–2·5)
Treated for syphilis 0·0% (0·0–0·0) 0·0% (0·0–21·7)
Screened for anaemia 27·9% (5·0–54·0) 34·7% (4·0–53·5)
Screened for proteinuria 4·4% (0·2–10·7) 0·8% (0·0–3·7)
Screened for HIV 97·9% (91·2–98·2) 91·2% (82·8–97·6)
Maternal age <20 years 16·5% (12·4–19·0) 17·6% (15·6–20·8)
Incomplete primary 
school
13·6% (10·1–27·3) 22·4% (18·9–26·9)
Married or with partner 88·5% (86·2–91·2) 89·1% (84·2–90·6)
No previous pregnancies 21·4% (19·2–22·9) 25·9% (23·7–28·1)
Previous abortion 28·9% (14·7–30·6) 21·8% (12·6–29·4)
Previous preterm birth 2·6% (1·6–4·3) 3·1% (2·0–3·4)
Previous low birthweight 
baby
2·4% (0·7–5·1) 5·1% (1·9–7·0)
Previous babies with 
congenital anomalies
0·0% (0·0–0·3) 0·1% (0·0–1·1)
Previous syphilis 
infection
0·6% (0·0–1·8) 0·4% (0·0–1·0)
Gestational age at first 
visit ≤20 weeks
48·0% (37·6–52·5) 46·5% (42·6–53·6)
Data are N, mean (SD), n (%), or median (IQR). The clinic is the unit of analysis. 
Health provider is the antenatal health-care provider that works in each 
participating clinic attending the mothers for antenatal care during pregnancy.
Table 1: Characteristics of antenatal care clinics and women at baseline
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No adverse reactions were reported among the 
1422 women who received benzathine benzylpenicillin 
treatment at their first visit at all participating clinics. 
Only one seropositive woman received erythromycin 
treatment.
Discussion
In this cluster randomised controlled trial, we showed 
that in antenatal care clinics in Kinshasa and Lusaka, a 
behavioural intervention, including the use of opinion 
leaders, academic detailing visits, reminders, audit and 
feedback, and supportive supervision, combined with 
the provision of kits with supplies, resulted in almost 
100% of pregnant women being screened during 
antenatal care, and 100% of seropositive women being 
treated at the first visit. Our results showed that for every 
1000 pregnant women attending antenatal care in clinics 
applying our intervention, 61 more women were 
screened for syphilis than in similar clinics receiving 
supplies only. Moreover, for every 1000 pregnant women 
found seropositive for syphilis at screening, 568 more 
women were treated during their first antenatal care visit 
in the clinics receiving the multifaceted intervention 
than in the clinics receiving supplies only. No effects 
were observed on other antenatal care practices not 
targeted by the intervention, including screening for 
anaemia, HIV, and proteinuria.
This trial had several strengths. The experimental 
design was rigorous and attained similar groups by using 
covariate-constrained randomisation. Careful training 
and monitoring of data collectors, who were independent 
from the antenatal care clinics, resulted in unbiased high-
quality data acquisition with no missing data on primary 
outcomes. The selected behavioural strategies using 
the conceptual framework of diffusion theory15 were docu-
mented as effective in changing behaviour8 and were 










Clinics (n=13), median 
proportion† (IQR)
Primary outcomes
Women screened for syphilis 18 314/18 357 99·9% (99·0 to 100·0) 17 036/17 679 93·8% (85·0 to 98·9) 6·1% (1·1 to 14·1) 0·00092
Women treated (proportion of 
those positive for syphilis)‡
889/894 100·0% (99·7 to 100·0) 534/991 43·2% (2·6 to 83·2) 56·8% (12·8 to 99·0) 0·0028
Secondary outcomes
Women screened for anaemia at 
their first clinic visit
8666/18 357 50·0% (22·3 to 75·8) 8097/17 679 57·0% (27·7 to 70·5) –7·0% (–24·9 to 30·8) 0·72
Women screened for proteinuria 
at their first clinic visit
2171/18 355 0·8% (0·3 to 7·2) 1458/17 677 0·1% (0·0 to 1·8) 0·7% (–0·2 to 6·3) 0·22
Women screened for HIV at their 
first clinic visit
15 422/18 320 86·5% (78·1 to 90·5) 14 189/17 678 81·1% (68·4 to 84·8) 5·4% (–2·4 to 15·9) 0·10
*Wilcoxon rank sum test. †The clinic is the unit of analysis. ‡For three clinics in the control group in the Democratic Republic of the Congo, the proportion of women screened 
positive for syphilis who were treated at the first visit could not be calculated because the clinic had no women who were positive for syphilis.
Table 2: Effect of the intervention on syphilis screening and treatment rates at the first antenatal care visit
Figure 2: Syphilis screening and treatment across the clinics
(A) Proportions of women screened at each of the 26 clinics. Numbers below bars are number of women screened over 
number of pregnant women attending clinic. (B) Proportions of women treated at the 23 clinics. Three clinics had no 
seropositive women, so proportion treated could not be calculated, and these clinics are not included on the graph. 
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tailored according to formative research.16 Furthermore, 
these strategies were successfully integrated into routine 
care in representative clinics of the existing health 
systems in both countries, suggesting that the observed 
effects might be similar in antenatal care programmes 
incorporating these components.
The study had some limitations. The main aim of the 
study was to improve syphilis screening and treatment at 
the first antenatal care visit; however, for ethical reasons, 
all women not treated at their first visit in either the 
control or intervention group were followed up to ensure 
as far as is possible that all seropositive women were 
treated before delivery of their child. This decision 
prevented the study from assessing the effect of the 
intervention on treatment during the whole pregnancy 
period or on perinatal outcomes at delivery. Although the 
study enrolled more than 18 000 pregnant women, the 
very small numbers of women who were seropositive in 
the Kinshasa clinics were unanticipated when we selected 
the clinics. Of the nearly 2000 women screened sero-
positive for syphilis in both cities, only 32 were from 
clinics in Kinshasa. These low figures prevented the study 
team from calculating infection rates in three control 
clinics and yielded a very small cluster size for the 
remaining clinics in Kinshasa. Nevertheless, restricting 
the analysis to clinics in Zambia showed a similar and 
statistically significant positive effect of the intervention 
on the treatment outcome. Additionally, the behavioural 
intervention was implemented as a package; thus, the 
contribution of each specific behavioural component 
cannot be disentangled from the overall inter vention 
effect. Furthermore, in the context of a pragmatic 
implementation trial, point-of-care tests were used in 
routine field conditions and quality assurance tests were 
not done.
The intervention combining the provision of supplies 
with behavioural components was associated with screen-
ing of practically 100% of pregnant women. However, 
providing only supplies also attained high coverage, 
with screening rates of 94%. Whether the difference in 
screening coverage between the two strategies is important 
from a public health perspective is a matter of discussion. 
The sole provision of supplies accompanied with minimal 
training seems to be enough to achieve high proport ions of 
women screened, and the difference that can be attained 
by adding the behavioural strategies might not be worth 
the complexity and costs of implementing and maintaining 
such interventions. This finding is in agreement with a 
recently published imple mentation research antenatal 
care trial in Mozambique,6 in which the provision of kits 
with supplies led to syphilis screening of 95·5% of 
patients. Using HIV-syphilis dual tests is another promis-
ing approach to increase syphilis screen ing.21 However, in 
our study, the provision of supplies alone resulted in 
syphilis treatment on the day of testing in less than 50% of 
seropositive women. The addition of a behavioural com-
ponent increased treatment up to 100%, suggesting that it 
changed some entrenched attitudes against immedi ate 
treatment on the same day, such as unawareness that one 
dose of benzathine benzylpenicillin is enough to prevent 
mother-to-child syphilis transmission and con cerns about 
potential adverse reactions to benzathine benzylpenicillin.16 
The effects on proportions of patients treated also agree 
with the antenatal care trial in Mozambique.6 In that study, 
the provis ion of kits with supplies for syphilis rapid 
screening and treatment increased the propor tions treated 
from 60·8% to 86·2%, a smaller effect than that observed 
for screen ing. Similarly, one cluster trial assessing point-
of-care syphilis screening with test results on the same day 
showed no differences in proportions of patients treated 
com pared with conventional laboratory strategies.22 To our 
know ledge, only one cluster trial, done in Ulaanbaatar, 
Mongolia, assessing a point-of-care screening strategy, 
showed treatment in more than 95% of participants.23 
Notably, in that study, the proportions of patients treated 
in clinics using conventional laboratory screening methods 
were almost 90%, which is higher than the propor tions at 
baseline or in control groups in the studies conducted in 
sub-Saharan Africa.6,22
The absence of observed effects on other antenatal care 
screening practices, such as screening for anaemia, 
Figure 3: Syphilis screening and treatment by study month
Proportions of women screened of total number of pregnant women attending clinic (A) and proportions of 
women treated of total number of women who tested seropositive for syphilis (B) over the baseline and follow-up 
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proteinuria, or HIV, suggests that the effects of our syph-
ilis intervention did not affect practices not specifically 
targeted by the intervention.
In summary, a behavioural intervention, together with 
the provision of supplies, can achieve syphilis screening 
and treatment in more than 95% of women, which is 
the suggested coverage proposed by WHO towards the 
elimination of mother-to-child transmission of syphilis.4,5 
The sole provision of supplies is sufficient to reach such 
levels of screening coverage but is not sufficient to ensure 
high levels of treatment.
In our opinion, the results of the trial are generalisable 
to antenatal care clinics in large urban settings of sub-
Saharan countries. Further research is needed to assess 
the cost-effectiveness of this strategy and its generalisability 
to other geographic areas and cultures as well as to other 
care practices. Attrition between diagnosis and appropriate 
care is a consistent challenge in health care, including 
major infectious disease programmes such as HIV and 
tuberculosis.24,25 Similar methods have proven effective in 
changing provider behaviour for other conditions.8,26,27
Further research could establish whether the behav-
ioural intervention could be simplified without decreasing 
its effect.
Contributors
PB and FA conceived and designed the study. EC and AKT contributed 
to the original idea. PB, XX, FA, MLC, and MBer developed the protocol 
in collaboration with all members of the Strategic and Technical 
Advisory Group (FD, CB, WAC, JB, EC, AKT, JL, and LP-M). MLC, KK, 
MBer, and AC prepared manuals in collaboration with staff members 
from the data coordinating centre. FA and PB coordinated the overall 
execution of the trial. AKM, DMN, JDW, PDL, MM, AMT, FHM, and 
EBa coordinated the implementation of the study at country level. 
EGE, MLC, MBer, AM, and CS participated in the implementation of 
the study and the intervention and data acquisition coordination. 
EBe and LG wrote the plan of analysis and conducted the statistical 
analysis. FA, PB, MLC, MBer, KK, and EGE interpreted the results. 
FA wrote the report with input from all authors, especially PB, XX, MLC, 
EBe, LG, KK, CS, EGE, MBel, and MBer.
Declaration of interests
We declare no competing interests.
Data sharing
De-identified individual participant data (including data dictionaries) and 
data collected during the trial that underlie the results reported here and 
the study protocol will be available online for 5 years from publication of 
this Article. Anyone who wishes can access the data for any purpose 
without restriction.
Acknowledgments
The authors would like to thank the Kinshasa and Lusaka teams for 
their contributions to the study. We thank the Democratic Republic 
of the Congo data team, consisting of the cluster coordinators 
Kiavia Balakasa Eder, Munduku Lukianame Gerce Lucide, and 
David Kampilu Kamwhbu; the data collectors Nsoo Likaba Seraphine, 
Dembo Djemba Georgette, Tewo Mbale Michel, Lukenso Wumba Jolie, 
Ntambua Mushiya Sarah, Diasitua Londa Claire, 
Kowanza Akondjaka Sophia, Kabedi Ngandu Deborah, Pala Dende Gisele, 
Manzanza Kaba Therèse, and Amatu Mikuib Venant; the local 
coordination team Bafuana B Aime and Palako Eloko Jolie; and the data 
managers Emo Mahilu Georges and Zingi ka Bagalama Sarahel. 
We thank the Democratic Republic of the Congo intervention team, 
consisting of the facilitators at intervention clinics Odia Tshibangu Rose 
and Tshimbalanga David (La Promesse clinic), Konga Mbalanda and 
Misenga Malunau Clementine (Centenaire clinic), Efomi Ndika Véro and 
M Ngonzo-Kay (Monaco Clinic), Nzumba Dondo and 
Nkanga Luc Ndontoni Sunda (Major Leka Clinic), Vungu Dibi Alexis 
(Bibua Clinic), Bonyara Bonyara Beatrice and Lakal Mumvudi Alain 
(Mobikisi Clinic), Lukutu Makab (Etonga Clinic), 
and Schola Koetana Adjomy (Rapha Clinic). We thank the Zambia data 
team, consisting of the data collectors Justine Chamanga, 
Pamela Malundu, Sydney Nawa, Evita Chambeshi, Peter Chisenga, 
Josephine Daka, Fredrick Kabamba, Carolyn M Kaite, Lisa M Lisuba, 
Khaku Lubasi, Tombozi Lupoleka, Vine Mukuka, Handy Robert Muwowo, 
Teddy Chota Mwananshiku, Samson Phiri, Precious Phiri, and 
Rajab L Sikalangwe; the data entry clerks Esther Nsama Nsemiwe, 
Gideon M Nyirenda, Michael Mkandawire, Lumota Mwambazi, 
Sampa Nsunge, Morgan Salin, Gift Sikombe, and Stephen Wamunyima; 
the local trial coordinators Charity Kaluma and Mulima Muzeya; the data 
coordinator Mwansa Chimfwembe; the general data manager 
Friday Habulembe Mwanakalanga; and the data consultant Ernest Banda. 
We also thank the Zambia intervention team, Zambia intervention 
coordinator Abigail Mwapule Tembo. We thank the facilitators at 
intervention clinics: Alice Kahimbi, Beth Kaunga Mubili, 
and Maureen Mwango (Chazanga Clinic), Evelyn Chipimo Kapasa, 
Mary Luchembe Mumbi, Nsama Mulenga, and Lucy Bweupe Chanda 
(Railway Clinic), Bertha Mulako Mulemwa, Maudy Lwali, and 
Lovely Muhyoka Chipanda (Chilenje Clinic), Gilberther Phiri Mulenga 
and Chenela Lungu Chansa (Lilay Clinic), and Veronica Lubumba Zulu, 
Caroline Zulu Maoka, Chola Queen Mulando, Sussie Muyangana, 
and Prisca Muwowo (Chainda Clinic). We thank the following Institute 
for Clinical Effectiveness and Health Policy Data Center Members, 
Candela Stella, Rocio Rodriguez, and Camila Rodriguez for their support 
to the study data management. We thank Andie Meyer for her continuous 
support in the study management and manuscript editing. We thank the 
members of the Data Safety Monitoring Board, Ana Pilar Betran, 
Dennis Wallace, and Stephen Munjanja. The authors’ views do not 
necessarily represent those of the Bill & Melinda Gates Foundation.
References
1 Gomez GB, Kamb ML, Newman LM, Mark J, Broutet N, 
Hawkes SJ. Untreated maternal syphilis and adverse outcomes of 
pregnancy: a systematic review and meta-analysis. 
Bull World Health Organ 2013; 91: 217–26.
2 De Santis M, De Luca C, Mappa I, et al. Syphilis infection during 
pregnancy: fetal risks and clinical management. 
Infect Dis Obstet Gynecol 2012; 2012: 430585.
3 Wijesooriya NS, Rochat RW, Kamb ML, et al. Global burden of 
maternal and congenital syphilis in 2008 and 2012: a health systems 
modelling study. Lancet Glob Health 2016; 4: e525–33.
4 WHO. Global guidance on criteria and processes for validation: 
elimination of mother-to-child transmission of HIV and syphilis, 
second edition. Geneva: World Health Organization, 2017. 
http://apps.who.int/iris/bitstream/handle/10665/259517/97892 
41513272-eng.pdf;jsessionid=13802031C0D5AFBB06877BDF9 
AA43F01?sequence=1 (accessed April 30, 2018).
5 WHO. WHO guideline on syphilis screening and treatment for 
pregnant women. Geneva: World Health Organization, 2017. 
http://apps.who.int/iris/bitstream/10665/259003/1/9789241550093-
eng.pdf (accessed April 30, 2018).
6 Betrán AP, Bergel E, Griffin S, et al. Provision of medical supply kits 
to improve quality of antenatal care in Mozambique: a stepped-wedge 
cluster randomised trial. Lancet Glob Health 2018; 6: e57–65.
7 Nurse-Findlay S, Taylor MM, Savage M, et al. Shortages of 
benzathine penicillin for prevention of mother-to-child 
transmission of syphilis: an evaluation from multi-country surveys 
and stakeholder interviews. PLoS Med 2017; 14: e1002473.
8 Althabe F, Buekens P, Bergel E, et al. A behavioral intervention to 
improve obstetrical care. N Engl J Med 2008; 358: 1929–40.
9 Althabe F, Alemán A, Berrueta M, et al. A multifaceted strategy to 
implement brief smoking cessation counseling during antenatal 
care in Argentina and Uruguay: a cluster randomized trial. 
Nicotine Tob Res 2016; 18: 1083–92.
10 Althabe F, Belizán JM, McClure EM, et al. A population-based, 
multifaceted strategy to implement antenatal corticosteroid treatment 
versus standard care for the reduction of neonatal mortality due to 
preterm birth in low-income and middle-income countries: the ACT 
cluster-randomised trial. Lancet 2015; 385: 629–39.




www.thelancet.com/lancetgh   Vol 7   May 2019 e663
11 Berrueta M, Cafferata ML, Mwenechanya M, et al. Syphilis 
screening and treatment in pregnant women in Kinshasa, 
Democratic Republic of the Congo and in Lusaka, Zambia: 
a cross-sectional study. Gates Open Res 2017; 1: 13.
12 Taljaard M, Weijer C, Grimshaw JM, Eccles MP. The Ottawa 
statement on the ethical design and conduct of cluster randomised 
trials: precis for researchers and research ethics committees. 
BMJ 2013; 346: f2838.
13 Berrueta M, Cafferata ML, Mwenechanya M, et al. Syphilis screening 
and treatment in pregnant women in Kinshasa, Democratic Republic 
of the Congo and in Lusaka, Zambia: a cross-sectional study. 
Gates Open Res 2017; 1: 13.
14 Ivers NM, Halperin IJ, Barnsley J, et al. Allocation techniques for 
balance at baseline in cluster randomized trials: a methodological 
review. Trials 2012; 13: 120.
15 Rogers EM. Diffusion of innovations. 3rd edn. New York: 
Free Press, 1983.
16 Nkamba D, Mwenechanya M, Kilonga AM, et al. Barriers and 
facilitators to the implementation of antenatal syphilis screening 
and treatment for the prevention of congenital syphilis in the 
Democratic Republic of Congo and Zambia: results of qualitative 
formative research. BMC Health Serv Res 2017; 17: 556.
17 Hiss RG, MacDonald R, Davis WK. Identification of physician 
educational influences in small community hospital. 
In: Proceedings of the 17th Annual Conference on Research in 
Medical Education. Washington, DC: Assocation of American 
Medical Colleges, 1978: 283–88.
18 Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of 
interventions: template for intervention description and replication 
(TIDieR) checklist and guide. BMJ 2014; 348: g1687.
19 Hollander M, Wolfe DA, Chicken E. Nonparametric statistical 
methods. 3rd edn. New York: John Wiley, 2013.
20 Raab GM, Butcherb I. Randomization inference for balanced 
cluster-randomized trials. Clin Trials 2005; 2: 130–40.
21 Gliddon HD, Peeling RW, Kamb ML, Toskin I, Wi TE, Taylor MM. 
A systematic review and meta-analysis of studies evaluating the 
performance and operational characteristics of dual point-of-care 
tests for HIV and syphilis. Sex Transm Infect 2017; 93: S3–15.
22 Myer L, Wilkinson D, Lombard C, Zuma K, Rotchford K, Karim SS. 
Impact of on-site testing for maternal syphilis on treatment delays, 
treatment rates, and perinatal mortality in rural South Africa: 
a randomised controlled trial. Sex Transm Infect 2003; 79: 208–13.
23 Munkhuu B, Liabsuetrakul T, Chongsuvivatwong V, McNeil E, 
Janchiv R. One-stop service for antenatal syphilis screening and 
prevention of congenital syphilis in Ulaanbaatar, Mongolia: 
a cluster randomized trial. Sex Transm Dis 2009; 36: 714–20.
24 Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. 
Can the UNAIDS 90-90-90 target be achieved? A systematic analysis 
of national HIV treatment cascades. BMJ Glob Health 2016; 
1: e000010.
25 Chin DP, Hanson CL. Finding the missing tuberculosis patients. 
J Infect Dis 2017; 216 (suppl 7): S675–78.
26 Semitala FC, Camlin CS, Wallenta J, et al. Understanding uptake of 
an intervention to accelerate antiretroviral therapy initiation in 
Uganda via qualitative inquiry. J Int AIDS Soc 2017; 20: 4.
27 Amanyire G, Semitala FC, Namusobya J, et al. Effects of a 
multicomponent intervention to streamline initiation of 
antiretroviral therapy in Africa: a stepped-wedge cluster-randomised 
trial. Lancet HIV 2016; 3: e539–48.
